Repli­cate Bio­science takes aim at mono-caus­ing virus af­ter promis­ing re­sults with mR­NA ra­bies shot

Repli­cate Bio­science, a San Diego start­up de­vel­op­ing a sec­ond-gen­er­a­tion mR­NA vac­cine tech­nol­o­gy that could spur stronger im­mu­ni­ty with small­er dos­es, said its ex­per­i­men­tal ra­bies shots per­formed bet­ter than ex­pect­ed in an 84-per­son clin­i­cal tri­al.

In an ex­clu­sive in­ter­view with End­points News, CEO Nathaniel Wang said his com­pa­ny plans to raise a Se­ries B round based on the ra­bies da­ta. But with­out a phar­ma or gov­ern­ment part­ner, Repli­cate is un­like­ly to ad­vance the ra­bies shot in­to a larg­er study, he added.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER